These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26052552)

  • 1. A mouse model of craniofacial bone lesion of tuberous sclerosis complex.
    Fang F; Wei X; Hu M; Liu F
    Musculoskelet Regen; 2015; 1(1):. PubMed ID: 26052552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural Crest-Specific TSC1 Deletion in Mice Leads to Sclerotic Craniofacial Bone Lesion.
    Fang F; Sun S; Wang L; Guan JL; Giovannini M; Zhu Y; Liu F
    J Bone Miner Res; 2015 Jul; 30(7):1195-205. PubMed ID: 25639352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
    Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
    J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
    Pal R; Xiong Y; Sardiello M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
    McEneaney LJ; Tee AR
    Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerotic bone lesions in tuberous sclerosis complex: A genotype-phenotype study.
    Boronat S; Barber I; Thiele EA
    Am J Med Genet A; 2017 Jul; 173(7):1891-1895. PubMed ID: 28488386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LysM-positive neurons drive Tuberous Sclerosis Complex (TSC)-associated brain lesions.
    Zhang J; Xu S; Liang K; Cao X; Ye Z; Huang W; Bai X; Zhang Y
    Cell Signal; 2022 Dec; 100():110468. PubMed ID: 36115548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of Decreased Rates of Cerebral Protein Synthesis
    Saré RM; Torossian A; Loutaev I; Smith CB
    eNeuro; 2022 Jul; 9(4):. PubMed ID: 35851298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
    Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
    Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
    Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
    Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mouse model of tuberous sclerosis complex (TSC): eye-specific Tsc1-ablation disrupts visual-pathway development.
    Jones I; Hägglund AC; Törnqvist G; Nord C; Ahlgren U; Carlsson L
    Dis Model Mech; 2015 Dec; 8(12):1517-29. PubMed ID: 26449264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
    Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous Sclerosis Complex.
    Wataya-Kaneda M
    Keio J Med; 2023 Aug; ():. PubMed ID: 37532517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberous sclerosis complex misdiagnosed as multiple metastases in a cervical cancer patient: case report and literature review.
    Ye T; Feng L; Peng M; Yuan S; Chen Y; Liu X; Chen J
    Ann Palliat Med; 2021 Oct; 10(10):11232-11238. PubMed ID: 34763482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic Mutations in
    Winden KD; Sundberg M; Yang C; Wafa SMA; Dwyer S; Chen PF; Buttermore ED; Sahin M
    J Neurosci; 2019 Nov; 39(47):9294-9305. PubMed ID: 31591157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic model to dissect the role of Tsc-mTORC1 in neuronal cultures.
    Nie D; Sahin M
    Methods Mol Biol; 2012; 821():393-405. PubMed ID: 22125080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.